At the Life Sciences Patents Network Europe 2016, a conference hosted in London by LSIPR, Thomas Kolzau of Enin Pharma led a roundtable on mature licensing strategies.
Kolzau explains: “Our company wants to license out substances for cancer therapy, as well as for second generation sequencing optimisation, and this of course needs licensing strategies.”